Effects of wild-type p53 expression on the quantity and activity of topoisomerase IIα and β in various human cancer cell lines

Journal of Cellular Biochemistry

Volumn 75, Issue 2, 1999, Pages 245-257

  Hochhauser, Daniel ^a   Valkov, Nikola I ^b   Gump, Jana L ^b   Wei, Irene ^b   O'Hare, Carolyn ^c   Hartley, John ^c   Fan, Jianguo ^a   Bertino, Joseph R ^a   Banerjee, Debabrata ^a   Sullivan, Daniel M ^b,d  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d NONE   (United States)

Author keywords

Drug sensitivity; Immunofluorescence; P53; Topoisomerase II; VP 16

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ETOPOSIDE; PROTEIN P53; RAZOXANE;

ARTICLE; CANCER CELL CULTURE; CELL STRAIN HL 60; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0033232044     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4644(19991101)75:2<245::AID-JCB7>3.0.CO;2-G     Document Type: Article

References (50)

1. Agarwal ML, Taylor WR, Chernov MV, Chernova OB, Stark GR. 1998. The p53 network. J Biol Chem 273:1-4.
2. Austin CA, Marsh KL, Wasserman RA, Willmore E, Sayer PJ, Wang JC, Fisher LM. 1995. Expression, domain structure, and enzymatic properties of an active recombinant human DNA topoisomerase IIβ. J Biol Chem 270:15739-15746.
3. Banerjee D, Lenz H-J, Schnieders B, Manno DJ, Ju JF, Spears CP, Hochhauser D, Danenberg K, Danenberg P, Bertino JR. 1995. Transfection of wild-type but not mutant p53 induces early monocytic differentiation in HL60 cells and increases their sensitivity to stress. Cell Growth Diff 6:1405-1413.
4. Blandino G, Levine AJ, Oren M. 1999. Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18:477-485.
5. Boege F, Andersen A, Jensen S, Zeidler R, Kreipe H. 1995. Proliferation-associated nuclear antigen Ki-S1 is identical with topoisomerase IIα. Am J Pathol 146: 1302-1308.
6. Brenner L, Muñoz-Antonia T, Vellucci VF, Zhou Z-l, Reiss M. 1993. Wild-type p53 tumor suppressor gene restores differentiation of human squamous carcinoma cells but not the response to transforming growth factor β. Cell Growth Diff 4:993-1004.
7. Bueso-Ramos CE, Yang Y, deLeon E, McCown P, Stass SA, Albitar M. 1993. The human MDM-2 oncogene is overexpressed in leukemias. Blood 82:2617-2623.
8. Davies SM, Robson CN, Davies SL, Hickson ID. 1988. Nuclear topoisomerase II levels correlate with the sensitivity of mammalian cells to intercalating agents and epipodophyllotoxins. J Biol Chem 263:17724-17729.
9. Deffie AM, Batra JK, Goldenberg GJ. 1989. Direct correlation between DNA topoisomerase II activity and cytotoxicity in Adriamycin-sensitive and resistant P388 leukemia cell lines. Cancer Res 49:58-62.
10. Ehinger M, Nilsson E, Persson A-M, Olsson I, Gullberg U. 1995. Involvement of the tumor suppressor gene p53 in tumor necrosis factor-induced differentiation of the leukemic cell line K562. Cell Growth Diff 6:9-17.
11. Ehinger M, Bergh G, Olofsson T, Baldetorp B, Olsson I, Gullberg U. 1996. Expression of the p53 tumor suppressor gene induces differentiation and promotes induction of differentiation by 1,25 dihydroxycholecalciferol in human leukemic U-937 cells. Blood 87:1064-1075.
12. Ehinger M, Bergh G, Johnsson E, Gullberg U, Olsson I. 1997. The tumor suppressor gene p53 can mediate transforming the growth factor β1-induced differentiation of leukemic cells independently of activation of the retinoblastoma protein. Cell Growth Diff 8:1127-1137.
13. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825.
14. Fan J, Bertino JR. 1997. K-ras modulates the cell cycle via both positive and negative regulatory pathways. Oncogene 14:2595-2607.
15. Fan S, El-Deiry WS, Bae I, Freeman J, Jondle D, Bhatia K, Fornace AJ, Magrath I, Kohn KW, O'Connor PM. 1994. p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 54:5824-5830.
16. Feldhoff PW, Mirski SEL, Cole SPC, Sullivan DM. 1994. Altered subcellular distribution of topoisomerase IIα in a drug-resistant human small cell lung cancer cell line. Cancer Res 54:756-762.
17. Fourie AM, Hupp TR, Lane DP, Sang B-C, Barbosa MS, Sambrook JF, Gething M-JH. 1997. HSP70 binding sites in the tumor suppressor protein p53. J Biol Chem 272: 19471-19479.
18. Gobert C, Bracco L, Rossi F, Olivier M, Tazi J, Lavelle F, Larsen AK, Riou J-F. 1996. Modulation of DNA topoisomerase I activity by p53. Biochemistry 35:5778-5786.
19. Hansen S, Hupp TR, Lane DP. 1996. Allosteric regulation of the thermostability and DNA binding activity of human p53 by specific interacting proteins. J Biol Chem 271: 3917-3924.
20. Iwadate Y, Tagawa M, Fujimoto S, Hirose M, Namba H, Sueyoshi K, Sakiyama S, Yamaura A. 1998. Mutation of the p53 gene in human astrocytic tumours correlates with increased resistance to DNA-damaging agents but not to anti-microtubule anti-cancer agents. Br J Cancer 77:547-551.
21. Ju JF, Banerjee D, Lenz HJ, Danenberg KD, Schmittgen TC, Spears CP, Schonthal AH, Manno DJ, Hochhauser D, Bertino JR, Danenberg PV. 1998. Restoration of wild-type p53 activity in p53-null HL-60 cells confers multi-drug sensitivity. Clin Cancer Res 4:1315-1322.
22. Kaufmann SH, McLaughlin SJ, Kastan MB, Liu LF, Karp JE, Burke PJ. 1991. Topoisomerase II levels during granulocytic maturation in vitro and in vivo. Cancer Res 51: 3534-3543.
23. Ko LJ, Prives C. 1996. p53: Puzzle and paradigm. Genes Dev 10:1054-1072.
24. Kohn KW, Ewig RAG, Erickson LAC, Zwelling LA. 1981. Measurement of strand breaks and crosslinks in DNA by alkaline elution. In: Friedberg EC, Hanawalt P, editors. DNA repair, a laboratory manual of research procedures. Vol 1B. New York: Marcel Dekker. p 379-401.
25. Kremenetskaya OS, Logacheva NP, Baryshnikov AY, Chumakov PM, Kopnin BP. 1997. Distinct effects of various p53 mutants on differentiation and viability of human K562 leukemia cells. Oncol Res 9:155-166.
26. Lowe SW, Ruley HE, Jacks T, Housman DE. 1993. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967.
27. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Jacks T. 1994. p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810.
28. Martinez JD, Pennington ME, Craven MT, Warters RL, Cress AE. 1997. Free radicals generated by ionizing radiation signal nuclear translocation of p53. Cell Growth Diff 8:941-949.
29. Megonigal MD, Rappaport EF, Nowell PC, Lange BJ, Felix CA. 1998. Potential role for wild-type p53 in leukemias with MLL gene translocations. Oncogene 16:1351-1356.
30. Mummenbrauer T, Janus F, Müller B, Wiesmüller L, Deppert W, Grosse F. 1996. p53 protein exhibits 3'-to-5' exonuclease activity. Cell 85:1089-1099.
31. Nelson WG, Kastan MB. 1994. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 14:1815-1823.
32. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJJr, Kohn KW. 1997. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57:4285-4300.
33. Preudhomme C, Fenaux P. 1997. The clinical significance of mutations of the p53 tumour suppressor gene in haematological malignancies. Br J Haematol 98:502-511.
34. Prokocimer M, Shaklai M, Ben Bassat H, Wolf D, Goldfinger N, Rotter V. 1986. Expression of p53 in human leukemia and lymphoma. Blood 68:113-118.
35. Qiu J, Catapano CV, Fernandes DJ. 1996. Formation of topoisomerase IIα complexes with nascent DNA is related to VM-26-induced cytotoxicity. Biochemistry 35: 16354-16360.
36. Roca J, Ishida R, Berger JM, Andoh T, Wang JC. 1994 Antitumor bisdioxopiperazines inhibit yeast DNA topoisomerase II by trapping the enzyme in the form of a closed protein clamp. Proc Natl Acad Sci USA 91:1781-1785.
37. Ronen D, Schwartz D, Teitz Y, Goldfinger N, Rotter V. 1996. Induction of HL-60 cells to undergo apoptosis is determined by high levels of wild-type p53 protein whereas differentiation of the cells is mediated by lower p53 levels. Cell Growth Diff 7:21-30.
38. Samuelson AV, Lowe SW. 1997. Selective induction of p53 and chemosensitivity in RB-deficient cells by E1A mutants unable to bind the RB-related proteins. Proc Natl Acad Sci USA 94:12094-12099.
39. Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D, Boyd MR. 1988. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 48:4827-4833.
40. Soddu S, Blandino G, Citro R, Scardigli R, Piaggio, Ferber, A, Calabretta B, Sacchi A. 1994. Wild-type p53 gene expression induces granulocytic differentiation of HL-60 cells. Blood 83:2230-2237.
41. Sugrue MM, Shin DY, Lee SW, Aaronson SA. 1997. Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53. Proc Natl Acad Sci USA 94:9648-9653.
42. Sullivan DM, Latham MD, Ross WE. 1987. Proliferation-dependent topoisomerase II content as a determinant of antineoplastic drug action in human, mouse, and Chinese hamster ovary cells. Cancer Res 47:3973-3979.
43. Sullivan DM, Latham MD, Rowe TC, Ross WE. 1989. Purification and characterization of an altered topoisomerase II from a drug-resistant Chinese hamster ovary cell line. Biochemistry 28:5680-5687.
44. Sullivan DM, Eskildsen LA, Groom KR, Webb CD, Latham MD, Martin AW, Wellhausen SR, Kroeger PE, Rowe TC. 1993. Topoisomerase II activity involved in cleaving DNA into topological domains is altered in a multiple drug resistant Chinese hamster ovary cell line. Mol Pharmacol 43:207-216.
45. Trepel M, Scheding S, Groscurth P, Horny H-P, Malipiero U, Brugger W, Dichgans J, Weller M. 1997. A new look at the role of p53 in leukemia cell sensitivity to chemotherapy. Leukemia 11:1842-1849.
46. Wang Q, Zambetti GP, Suttle DP. 1997. Inhibition of DNA topoisomerase IIα gene expression by the p53 tumor suppressor. Mol Cell Biol 17:389-397.
47. Webb CD, Latham MD, Lock RB, Sullivan DM. 1991. Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line. Cancer Res 51:6543-6549.
48. Wilson WH, Teruya-Feldstein J, Fest T, Harris C, Steinberg SM, Jaffe ES, Raffeld M. 1997. Relationship of p53, bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood 89:601-609.
49. Wiman KG. 1997. p53: Emergency brake and target for cancer therapy. Exp Cell Res 237:14-18.
50. Wolverton JS, Danks MK, Grenzen B, Beck WT. 1992. DNA topoisomerase II immunostaining in human leukemia and rhabdomyosarcoma cell lines and their responses to topoisomerase II inhibitors. Cancer Res 52:4248-4253.